Insulet PODD Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| Drug Delivery | $22.5M-34.0% | $34.1M-22.5% | $44M-6.8% | $47.2M+4.7% | $45.1M+15.9% | |
| International | $844.9M+12.0% | $754.3M+10.6% | $682.2M+10.4% | $618M+10.3% | $560.4M+7.1% | |
| Total Omnipod products | $2.88B+7.6% | $2.67B+7.9% | $2.48B+7.2% | $2.31B+7.4% | $2.15B+6.0% | |
| U.S.Omnipod | $2.03B+5.9% | $1.92B+6.9% | $1.8B+6.0% | $1.69B+6.3% | $1.59B+5.6% | |
| Property, plant and equipment, net by Geography | ||||||
| Malaysia | $769.8M+9.5% | $702.9M+9.5% | $642M— | —— | —— | |
| Other | $304.9M+67.5% | $182M+181% | $64.8M— | —— | —— | |
| U.S. | $1.87B-0.1% | $1.87B-0.2% | $1.88B— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Insulet break its business down?
- Insulet (PODD) reports total revenue by product across 4 parts — Drug Delivery, International, Total Omnipod products and U.S.Omnipod. Each is extracted from the segment footnotes and tracked over time.
- Where does Insulet's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Insulet's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
